Resultados de la búsqueda

González-Gómez A, Fernández-Golfín C, Hinojar R, Monteagudo JM, García A, García-Sebastián C, García-Lunar I, Sánchez-Recalde Á, Salido L, Pardo A, Zamorano JL. The 4A classification for patients with tricuspid regurgitation. Rev Esp Cardiol (2023) 76:845-851

Pascual-Figal D, Lax A, Asensio López MC. Circulating ST2, from biomarker to pathogenic mediator. Rev Esp Cardiol (2023) S1885-5857(23)00102-0
Link to the full text in Repisalud

Rodríguez-Leor O, Rosselló X, Cid-Álvarez AB, Pérez de Prado A. Results from the ACI-SEC Infarction Code Registry. The ECG also exists. Response. Rev Esp Cardiol (2023) S1885-5857(23)00109-3.

Vela Martín P, Matutano Muñoz A, Sánchez Ortiz D, Domínguez F, Royuela A, Cobo Marcos M. CANDI study: chlorthalidone vs acetazolamide in patients with diuretic resistance in acute heart failure. Rev Esp Cardiol (2023) 76:477-480

Barreiro-Pérez M, Pastor Pueyo P, Raposeiras-Roubín S, Montero Corominas D, Uribarri A, Eiros Bachiller R, Rozado Castaño J, García-Cuenllas Álvarez L, Serratosa Fernández L, Domínguez F, Pascual Figal D. Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management. Rev Esp Cardiol (2023) 76:555-563
Link to the full text in Repisalud

Castellano JM, Fuster V. Scientific development of the CNIC cardiovascular polypill: from conceptualization to clinical efficacy Rev Esp Cardiol (2023) 76:1055-1060

López-Azor JC, Delgado JF, Vélez J, Rodríguez R, Solís J, Del Oro M, Ortega C, Salguero-Bodes R, Palacios B, Vicent L, Moreno G, Rosillo N, Varela L, Capel M, Arribas F, Bernal JL, Bueno H. Differences in clinical outcomes, health care resource utilization and costs in heart failure patients according to left ventricular ejection fraction. Rev Esp Cardiol (2023) 76:862-871.

Arboleda-García A, Alarcon-Ruiz I, Boada-Acosta L, Boada Y, Vignoni A, Jantus-Lewintre E. Advancements in synthetic biology-based bacterial cancer therapy: A modular design approach. CRIT REV ONCOL HEMAT (2023) 190:104088
Link to the full text in Repisalud

Coelho T, Dispenzieri A, Grogan M, Conceição I, Waddington-Cruz M, Kristen AV, Wixner J, Diemberger I, Gonzalez-Moreno J, Maurer MS, Planté-Bordeneuve V, Garcia-Pavia P, Tournev I, Gonzalez-Costello J, Cariou E, González-Duarte A, Glass O, Chapman D, Amass L; THAOS investigators. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid (2023) 17:1-4
Link to the full text in Repisalud

Marqués M, Corral S, Sánchez-Díaz M, Del Pozo N, Martínez de Villarreal J, Schweifer N, Zagorac I, Hilberg F, Real FX. Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance. Mol Cancer Ther (2023) 22:616-629
Link to the full text in Repisalud